IV Amiodarone Dosing for Life-Threatening Ventricular Arrhythmias
For life-threatening ventricular tachycardia or ventricular fibrillation, administer IV amiodarone as a 150 mg bolus over 10 minutes, followed by 1 mg/min for 6 hours, then 0.5 mg/min for the remaining 18 hours, delivering approximately 1,050 mg total over 24 hours. 1, 2, 3
Initial Loading Protocol
The standard three-phase infusion regimen is:
- Rapid loading bolus: 150 mg IV diluted in 100 mL D5W over 10 minutes 1, 2, 3
- First maintenance phase: 1 mg/min for 6 hours (360 mg total) 1, 2, 3
- Second maintenance phase: 0.5 mg/min for remaining 18 hours (540 mg total) 1, 2, 3
This delivers approximately 1,000-1,050 mg over the first 24 hours. 1, 2
Cardiac Arrest Modification
For pulseless ventricular tachycardia or ventricular fibrillation unresponsive to defibrillation and epinephrine, give 300 mg IV/IO bolus over 10 minutes, with a second 150 mg bolus if the rhythm persists. 1, 2
Breakthrough Arrhythmias
If ventricular fibrillation or hemodynamically unstable ventricular tachycardia recurs during the maintenance infusion, repeat the initial 150 mg loading bolus over 10 minutes. 1, 3
Administration Requirements
Use a central venous catheter whenever possible, as peripheral administration causes severe phlebitis with concentrations >2 mg/mL. 2, 4 For infusions lasting >1 hour through a peripheral line, do not exceed 2 mg/mL concentration. 2 An in-line filter should be used during administration. 4
Dose-Response Evidence
Higher doses demonstrate superior efficacy. In a multicenter dose-ranging study of 342 patients, the 1,000 mg/24-hour regimen showed significantly longer time to first arrhythmic event compared to lower doses (125 mg or 500 mg), with median event rates of 0.02 events/hour versus 0.07 events/hour for the lowest dose. 5 The majority of patients who respond do so within the first 2 hours of therapy, with all responders showing effect within 84 hours. 6
Critical Monitoring Parameters
Monitor continuously for:
Hypotension: Occurs in 16-26% of patients receiving IV amiodarone 1, 2, 5
- Slow the infusion rate if hypotension develops
- Add vasopressor drugs, positive inotropic agents, or volume expansion as needed 3
Bradycardia and AV block: Occurs in 4.9% of IV patients 1, 4
QT prolongation: Common but rarely causes torsades de pointes 7, 1
Absolute Contraindications
Do not administer IV amiodarone in patients with second- or third-degree AV block, marked sinus bradycardia, or sick sinus syndrome unless a functioning pacemaker is in place. 2, 3 Cardiogenic shock and known hypersensitivity to amiodarone or iodine are also absolute contraindications. 3
Drug Interactions Requiring Immediate Action
- Digoxin: Reduce dose by 50% immediately, as amiodarone doubles digoxin levels 8, 4
- Warfarin: Reduce dose by 30-50% and check INR within 3-5 days, as amiodarone significantly increases anticoagulation 8, 4
- QT-prolonging drugs: Avoid concomitant use without expert consultation 2
Transition to Oral Therapy
When converting from IV to oral amiodarone:
- After <1 week IV: Start 800-1,600 mg oral daily 1, 8
- After 1-3 weeks IV: Start 600-800 mg oral daily 1, 8
- Continue oral loading until 10 grams total accumulated dose, then reduce to maintenance of 200-400 mg daily 1, 8
Begin oral dosing while IV infusion continues due to amiodarone's extremely long half-life (average 58 days, range 15-100 days). 8, 4
Common Pitfalls to Avoid
Do not use IV amiodarone in a patient with baseline bradycardia (heart rate <60 bpm) without a pacemaker unless the arrhythmia is immediately life-threatening and no safer alternatives exist. 4 The risk of severe bradycardia requiring pacing occurs in approximately 5% of patients. 4
Do not administer through small peripheral veins for prolonged periods, as phlebitis is nearly universal with concentrations >2 mg/mL. 2, 4